Status:
COMPLETED
An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastic Colorectal Cancer
Lead Sponsor:
Eli Lilly and Company
Conditions:
Metastatic Colorectal Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE1
Brief Summary
The purpose of this study is to predict response to Erbitux as a single agent in patients with metastatic colon cancer
Eligibility Criteria
Inclusion
- Measurable disease Tumor available for biopsies. Life expectancy of at least 3 months.
Exclusion
- Known or documented brain metastases prior to Cetuximab therapy.
Key Trial Info
Start Date :
December 1 2003
Trial Type :
INTERVENTIONAL
End Date :
February 1 2006
Estimated Enrollment :
110 Patients enrolled
Trial Details
Trial ID
NCT00207155
Start Date
December 1 2003
End Date
February 1 2006
Last Update
October 28 2015
Active Locations (14)
Enter a location and click search to find clinical trials sorted by distance.
1
Local Institution
Duarte, California, United States
2
Local Institution
Tampa, Florida, United States
3
Local Institution
Baltimore, Maryland, United States
4
Local Institution
St Louis, Missouri, United States